Charlotte Teunissen, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses the latest data on the use of body fluid biomarkers to monitor treatment effects in patients with multiple sclerosis (MS). Neurofilament light chain (NfL) has recently emerged as a promising biomarker that has been associated with measures of disease activity, disability worsening and brain atrophy. Dr Teunissen highlights NfL as a useful indicator of treatment effect that can guide clinician decision making. Additionally, NfL has been used to study treatment wearing off effects. Patients receiving ocrelizumab often report worsening MS-related symptoms just before their next dose, known as the wearing off phenomenon. Dr Teunissen talks on how NfL was used to assess if there was a true objective wearing-off effect. This interview took place during the European Academy of Neurology 2021 congress.
Research of Prof. Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association.
Prof. Teunissen is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds.
Prof. Teunissen has a collaboration contract with ADx Neurosciences and Quanterix, performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, Vivoryon.